TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05690620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied.
Study: NCT06275750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)
Description: The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
Study: NCT05090514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading and Growth Mindset
Description: Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control
Description: Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
Study: NCT04998747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: AMG 701 will be administered as SC or intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: AMG 701 will be administered as SC injection.
Study: NCT04907539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered via IV infusion, 480 mg q4w.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic
Study: NCT04390945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab combined with concurrent radiotherapy and chemotherapy
Study: NCT05711849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.
Description: Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).
Description: These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
Study: NCT04984993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED3000 (Male)
Description: Gel formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg (Male)
Description: Tablets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED3000 (Female)
Description: Gel formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg (Female)
Description: Tablets
Study: NCT05724069

Intervention type: DRUG
Group type: OTHER
Intervention: Velusetrag
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Velusetrag
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Velusetrag
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Velusetrag
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Study: NCT04832139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marstacimab PFP
Description: 300 milligrams (mg) subcutaneous injection marstacimab PFP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marstacimab PFP
Description: 300 milligrams (mg) subcutaneous injection marstacimab PFP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marstacimab PFS
Description: 300 mg subcutaneous injection of marstacimab PFS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marstacimab PFS
Description: 300 mg subcutaneous injection of marstacimab PFS
Study: NCT04702906

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Standard treatment if indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Standard treatment if indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimetazidine hydrochloride metacardia ® 20 mg tablet
Description: trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)
Study: NCT06484010

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAPPS Model of case presentation
Description: The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified.
Study: NCT04907968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1536 (Upifitamab Rilsodotin)
Description: Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1536 (Upifitamab Rilsodotin)
Description: Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles.
Study: NCT05915624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone counseiling
Description: One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
Study: NCT05724069

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Study: NCT06228040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preanaesthetic teleconsultation
Description: Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preanaesthetic classical physical consultation
Description: Pre-anaesthetic classical consultation before teleconsultation implementation
Study: NCT04905212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept 160mg
Description: Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept 240mg
Description: Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
Study: NCT05846906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: oral sildenafil (Respatio® 20mg )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: used for ovionulation induct
Study: NCT05630859

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo, administered intramuscularly.
Study: NCT05846906

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 50mg
Description: used for ovionulation induct
Study: NCT05259761

Intervention type: OTHER
Intervention: Unmanned ariel vehicle
Description: Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)

Intervention type: OTHER
Intervention: Unmanned ariel vehicle
Description: Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)

Intervention type: OTHER
Intervention: Unmanned ariel vehicle
Description: Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
Study: NCT05472077

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lollipop Swab
Description: The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop.
Study: NCT05913180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid 1000 MG
Description: 1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily starting day of elective gynecological surgery for 10 days
Study: NCT05675761

Intervention type: DRUG
Intervention: Azorubine
Description: Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)

Intervention type: DRUG
Intervention: Azorubine
Description: Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
Study: NCT05428488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (W12-W48)
Description: The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Inhibitor (W12-W48)
Description: In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Inhibitor (W0-W12)
Description: All included patients will receive TNF inhibitors subcutaneous for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor (W0-W12)
Description: All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
Study: NCT06302894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-sufficiency
Description: Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
Study: NCT05240560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.3656
Description: Histamine H3 receptor antagonist/inverse agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BP1.3656
Description: Histamine H3 receptor antagonist/inverse agonist
Study: NCT04860791

Intervention type: OTHER
Intervention: questionnaires
Description: Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
Study: NCT05828472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: MY008211A tablets, low/moderate/high dose orally, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: MY008211A tablets, low/moderate/high dose orally, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: MY008211A tablets, low/moderate/high dose orally, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: MY008211A tablets, low/moderate/high dose orally, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets matched placebo
Description: MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets matched placebo
Description: MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets matched placebo
Description: MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
Study: NCT05630859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NgG HTD investigational vaccine
Description: Two doses of NgG HTD investigational vaccine, administered intramuscularly.
Study: NCT05828472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets matched placebo
Description: MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
Study: NCT05630859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NgG below HTD investigational vaccine
Description: Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
Study: NCT04732611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
Study: NCT04765579

Intervention type: BEHAVIORAL
Intervention: visual analogy scala
Description: We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.

Intervention type: BEHAVIORAL
Intervention: visual analogy scala
Description: We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
Study: NCT06250985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of reimplantation
Description: Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of reimplantation
Description: Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
Study: NCT05962970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous adductor canal block (CACB) ropivacaine
Description: The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham continuous adductor canal block - ShACB NaCl
Description: sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
Study: NCT06088030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
Study: NCT05115487

Intervention type: DIAGNOSTIC_TEST
Intervention: digital dynamometer
Description: Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.

Intervention type: DIAGNOSTIC_TEST
Intervention: digital dynamometer
Description: Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
Study: NCT05995197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: action observation
Description: cartoon observation
Study: NCT04927104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK Knee Prosthesis
Description: After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.